


Development of immuno-cancer antibodies that improves single and/or combination anti-cancer efficacy by improving immune suppressive tumor microenvironments



ONCOLOGY	Candidate
Product Type	Immunoglobulin Product [Ab]
Indication	Solid Cancer
Target	B7 Homolog 3 (B7-H3) and TGFβ
MoA(Mechanism of Action)	Binding and inhibition of B7H3 → Binding to TGFβ → Endocytosis → Degradation of immune suppressive proteins
Competitiveness	First In Class <ul style="list-style-type: none"> • Bispecific antibody functions not only anti-cancer effects but also cancer targeting thus lowering the risk of off-target effects • At the same time, bispecific antibody leads to the degradation of immune suppressive cytokine
Development Stage	Candidate
Route of Administration	Intravenous